3β-methoxymethyl-3α-hydroxy-19-nor-pregnan-20-one | 1430064-06-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 3β-methoxymethyl-3α-hydroxy-19-nor-pregnan-20-one
• 英文别名: 1-[(3R,5R,8R,9R,10S,13S,14S,17S)-3-hydroxy-3-(methoxymethyl)-13-methyl-2,4,5,6,7,8,9,10,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone
• CAS: 1430064-06-4
• 化学式: C₂₂H₃₆O₃
• 分子量: 348.526
• InChiKey: JIWJWZQRCFJBIU-IIPSAPQISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3β-methoxymethyl-3α-hydroxy-19-nor-pregnan-20-one 在 溴 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 32.33h， 生成 (3R,5R,8R,9R,10S,13S,14S,17S)-3-hydroxy-3-(methoxymethyl)-13-methyl-2,4,5,6,7,8,9,10,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-carboxamide
  参考文献：
  名称：

  [EN] 3.ALPHA.-HYDROXY, 17.BETA.-C(O)-N-ARYL SUBSTITUTED NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF
  [FR] STÉROÏDES NEUROACTIFS 3.ALPHA.-HYDROXY, 17.BETA.-C(O)-N-ARYL-SUBSTITUÉS ET COMPOSITIONS ASSOCIÉES

  摘要：

  本文提供了一种公式(I)的化合物或其药学上可接受的盐，其中R2a，R2b，R3a，R4a，R4b，R5，R6，R7，R11a，R11b，R15a，R15b，R16，R17，R19，RX，RY和t在此定义。本文还提供了含有公式(I)的化合物的药物组合物和使用该化合物的方法，例如用于治疗中枢神经系统相关疾病。

  公开号：

  WO2021262836A1
• 作为产物：
  描述：

  (3R,5R,8R,9R,10S,13S,14S,17S)-17-(1-hydroxyethyl)-3-(methoxymethyl)-13-methyl-2,4,5,6,7,8,9,10,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol 在 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以42%的产率得到3β-methoxymethyl-3α-hydroxy-19-nor-pregnan-20-one
  参考文献：
  名称：

  WO2020118060A5

  摘要：

  公开号：

  WO2020118060A5

文献信息

• [EN] 3,3 DISUBSTITUTED 19-NOR PREGNANE COMPOUNDS, COMPOSITIONS, AND USES THEREOF<br/>[FR] COMPOSÉS 19-NOR-PRÉGNANE 3,3-DISUBSTITUÉS, COMPOSITIONS ET UTILISATIONS ASSOCIÉES
  申请人：SAGE THERAPEUTICS INC

  公开号：WO2013056181A1

  公开（公告）日：2013-04-18

  Provided herein are 3,3-disubstituted 19-nor- steroidal compounds according to Formula (I) and (III): where R1,R2, R3, R3', R4, R6a, R6a, R11a, and R11b are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, insomnia, anxiety, depression, traumatic brain injury (TBI), stress, and epilepsy.

  根据公式（I）和（III），提供了3,3-二取代19-去甲类固醇化合物：其中R1、R2、R3、R3'、R4、R6a、R6a、R11a和R11b如本文所定义。本发明的化合物被认为对预防和治疗各种与中枢神经系统相关的疾病有用，例如治疗睡眠障碍、情绪障碍、失眠、焦虑、抑郁、创伤性脑损伤（TBI）、压力和癫痫。
• [EN] 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF<br/>[FR] 19-NOR-STÉROÏDES NEUROACTIFS ET PROCÉDÉS D'UTILISATION DE CEUX-CI
  申请人：SAGE THERAPEUTICS INC

  公开号：WO2014169836A1

  公开（公告）日：2014-10-23

  Provided herein are 3,3-disubstituted19-nor-steroidal compounds according to Formula(I): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions,for example, treatment of sleep disorders, mood disorders,schizophrenia spectrum disorders, disorders of memory and/or cognition, movement disorders,personality disorders,autism spectrum disorders, pain,traumatic brain injury, vascular diseases,substance abuse disorders and/or withdrawal syndromes, tinnitus, status epilepticus.

  根据以下公式(I)，提供了3,3-二取代19-去甲类固醇化合物及其药物组合物。这些化合物被认为对预防和治疗各种与中枢神经系统相关的疾病有用，例如治疗睡眠障碍、情绪障碍、精神分裂症谱系障碍、记忆和/或认知障碍、运动障碍、人格障碍、自闭症谱系障碍、疼痛、创伤性脑损伤、血管疾病、物质滥用障碍和/或戒断综合征、耳鸣、癫痫持续状态。
• [EN] NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF<br/>[FR] STÉROÏDES NEUROACTIFS, LEURS COMPOSITIONS ET UTILISATIONS
  申请人：SAGE THERAPEUTICS INC

  公开号：WO2015180679A1

  公开（公告）日：2015-12-03

  Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I) : and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.

  本文提供了式(I)的19-去C3，3-二取代类固醇及其药用可接受的盐；其中R1、R2、R3和R4如本文所定义，A是包含3个或4个氮原子的杂环芳基环系统，如本文所定义。这些化合物被认为对预防和治疗各种与中枢神经系统相关的疾病有用，例如治疗睡眠障碍、情绪障碍、精神分裂症谱系障碍、癫痫性障碍、记忆和/或认知障碍、运动障碍、人格障碍、自闭症谱系障碍、疼痛、创伤性脑损伤、血管疾病、物质滥用障碍和/或戒断综合征，以及耳鸣症的治疗。
• [EN] NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF<br/>[FR] STÉROÏDES NEUROACTIFS ET COMPOSITIONS ASSOCIÉES
  申请人：SAGE THERAPEUTICS INC

  公开号：WO2020243488A1

  公开（公告）日：2020-12-03

  Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7a, R7a, R11a, R11b, R12a, R12b, R16a, R16b, R19, R11a, R22, RX, RY and n are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.

  本文提供了一种化合物Formula (I)或其药用盐，其中R1a、R1b、R2a、R2b、R3、R4a、R4b、R5、R6a、R6b、R7a、R7a、R11a、R11b、R12a、R12b、R16a、R16b、R19、R11a、R22、RX、RY和n在此定义。本文还提供了包括Formula (I)化合物的药物组合物以及使用这些化合物的方法，例如用于治疗中枢神经系统相关疾病。
• 19-NOR C3, 3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOF
  申请人：SAGE THERAPEUTICS, INC.

  公开号：US20170246191A1

  公开（公告）日：2017-08-31

  Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein , R 1 , R 2 , R 3a , R 3b , R 4a , R 4b , R 5 , R 6 , and R 7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.

  本文提供了式(I)的19-去氢C3,3-二取代C21-吡唑基类固醇及其药学上可接受的盐；其中，R1、R2、R3a、R3b、R4a、R4b、R5、R6和R7如本文所定义。这些化合物被认为对预防和治疗各种与中枢神经系统有关的疾病有用，例如，治疗睡眠障碍、情绪障碍、精神分裂谱系障碍、惊厥性障碍、记忆和/或认知障碍、运动障碍、人格障碍、自闭症谱系障碍、疼痛、创伤性脑损伤、血管疾病、物质滥用障碍和/或戒断综合征以及耳鸣等方面具有潜在作用。